Compare Crispr Therapeutics AG (CRSP) vs iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs iShares S&P GSCI Commodity-Indexed Trust ETF — how do they compare? Crispr Therapeutics AG trades at $50.88 (market cap $4.97B), while iShares S&P GSCI Commodity-Indexed Trust ETF trades at $30.93. The key difference: iShares S&P GSCI Commodity-Indexed Trust ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | GSG | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $76.78 | $34.77 |
52-Week Low | $44.34 | $22.06 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
GSG trades at $30.52, up 3.6% with a bullish technical signal. Moving averages and oscillators support upward momentum, though the 6-day RSI indicates overbought conditions. Recent news highlights institutional shifts toward commodities, aligning with GSG's focus. Key support lies near $30, with resistance at $31.
The outlook remains positive amid commodity-driven market themes, but overbought technicals and reliance on macroeconomic trends pose risks. Upside depends on sustained commodity demand and institutional inflows, while volatility may test near-term support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →
